Zaccarelli M - Search Results

1

Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.

Fabbiani M, Zaccarelli M, Grima P, Prosperi M, Fanti I, Colafigli M, D'Avino A, Mondi A, Borghetti A, Fantoni M, Cauda R, Di Giambenedetto S. Fabbiani M, et al. Among authors: zaccarelli m. BMC Infect Dis. 2014 Jan 13;14:26. doi: 10.1186/1471-2334-14-26. BMC Infect Dis. 2014. PMID: 24418191 Free PMC article.

2

Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.

De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Zaccarelli M, Tozzi V, Ammassari A, Murri R, Antinori A. De Luca A, et al. Among authors: zaccarelli m. AIDS. 2000 Jul 28;14(11):1655-6. doi: 10.1097/00002030-200007280-00022. AIDS. 2000. PMID: 10983653 No abstract available.

3

Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.

Antinori A, Baldini F, Girardi E, Cingolani A, Zaccarelli M, Di Giambenedetto S, Barracchini A, De Longis P, Murri R, Tozzi V, Ammassari A, Rizzo MG, Ippolito G, De Luca A. Antinori A, et al. Among authors: zaccarelli m. AIDS. 2001 Aug 17;15(12):1579-81. doi: 10.1097/00002030-200108170-00018. AIDS. 2001. PMID: 11504993

4

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.

Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, Di Giambenedetto S, Narciso P, Ammassari A, Girardi E, De Luca A, Perno CF. Antinori A, et al. Among authors: zaccarelli m. AIDS Res Hum Retroviruses. 2002 Aug 10;18(12):835-8. doi: 10.1089/08892220260190308. AIDS Res Hum Retroviruses. 2002. PMID: 12201905

5

Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.

Zaccarelli M, Perno CF, Forbici F, Cingolani A, Liuzzi G, Bertoli A, Trotta MP, Bellocchi MC, Di Giambenedetto S, Tozzi V, Gori C, D'Arrigo R, De Longis P, Noto P, Girardi E, De Luca A, Antinori A. Zaccarelli M, et al. Antivir Ther. 2003 Feb;8(1):51-6. Antivir Ther. 2003. PMID: 12713064

6

Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.

Zaccarelli M, Perno CF, Forbici F, Soldani F, Bonfigli S, Gori C, Trotta MP, Bellocchi MC, Liuzzi G, D'Arrigo R, De Longis P, Boumis E, Bellagamba R, Tozzi V, Narciso P, Antinori A. Zaccarelli M, et al. Clin Infect Dis. 2004 Feb 1;38(3):433-7. doi: 10.1086/381097. Epub 2004 Jan 6. Clin Infect Dis. 2004. PMID: 14727218

7

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.

Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF. Tozzi V, et al. Among authors: zaccarelli m. J Infect Dis. 2004 May 1;189(9):1688-95. doi: 10.1086/382960. Epub 2004 Apr 13. J Infect Dis. 2004. PMID: 15116307 Clinical Trial.

8

Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.

De Luca A, Cozzi-Lepri A, Antinori A, Zaccarelli M, Bongiovanni M, Di Giambenedetto S, Marconi P, Cicconi P, Resta F, Grisorio B, Ciardi M, Cauda R, Monforte Ad; I.Co.N.A; UCSC; IMIT-MI; INMI. De Luca A, et al. Among authors: zaccarelli m. Antivir Ther. 2006;11(5):609-18. Antivir Ther. 2006. PMID: 16964829

9

Safety and efficacy of regimens containing emtricitabine in HIV-infected patients taking highly active antiretroviral therapy.

Marconi P, Lorenzini P, Borrelli I, Liuzzi G, Sette P, Zaccarelli M, Antinori A. Marconi P, et al. Among authors: zaccarelli m. New Microbiol. 2006 Jul;29(3):169-75. New Microbiol. 2006. PMID: 17058783

10

Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis.

Cicconi P, Cozzi-lepri A, Orlando G, Matteelli A, Girardi E, Degli Esposti A, Moioli C, Rizzardini G, Chiodera A, Ballardini G, Tincati C, d'Arminio Monforte A; I.Co.N.A. Study Group. Cicconi P, et al. Infection. 2008 Feb;36(1):46-53. doi: 10.1007/s15010-007-6300-z. Epub 2008 Jan 29. Infection. 2008. PMID: 18231722

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

250 results

Search Page